GOUT MANAGEMENT AND MUTUAL PRODRUG THERAPY: A COMPREHENSIVE REVIEW AND ANALYSIS

M. P. Deekshitha*, C. R. Biju, G. Jyothisree, K. Ayswarya and C. Mirfa Sherin

ABSTRACT

Hyperuricemia and sudden flare-ups of arthritis are hallmarks of gout, an inflammatory arthritis type, poses significant challenges in management. Traditional approaches involve the separate administration of xanthine oxidase inhibitors (XOIs), non-steroidal anti-inflammatory medications (NSAIDs) to lessen inflammation and lower serum uric acid levels. However, the mutual prodrug strategy offers a promising avenue for combining the hypouricemic and anti-inflammatory effects within a single entity. This comprehensive review examines recent advancements in mutual prodrug formulations for gout treatment, encompassing synthesis, characterization, and pharmacological evaluation. The review explores the therapeutic potential of mutual prodrugs in streamlining treatment regimens, enhancing patient compliance, and improving clinical outcomes. Furthermore, it discusses safety considerations, analytical methodologies, and future directions in the development of mutual prodrug therapies for gout. By synthesizing current research findings, the purpose of this review is to shed light on how gout care is changing and how mutual prodrug therapy can help improve treatment plans.

Keywords: Gout, Mutual prodrugs, Hyperuricemia, Xanthine oxidase inhibitors.